Return to News Categories

Commentary and Educational Cattle - Hogs / Livestock News Currencies News Energy News Grain News Index News Interest Futures News Metals Futures News Reports: Crops, CFTC, etc Soft Commodities News

Futures and Commodity Market News

Cytori Therapeutics Announces Inducement Grants for New Employees


Cytori Therapeutics, Inc. (NASDAQ:CYTX) (the "Company"), announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on January 25, 2018 to four (4) new employees (the "Optionees") exercisable for an aggregate of up to 16,000 shares of the Company's common stock (the "Option Shares"), with a per share exercise price of $0.455, which was the closing price of Cytori's common stock on the Nasdaq Capital Market on January 25, 2018. The stock options have a ten-year term and vest over a period of four years, with one quarter of the Option Shares vesting on the first anniversary of each Optionee's employment commencement date with the Company, and with the remainder of the Option Shares vesting over the ensuing three years in thirty-six (36) equal, consecutive, monthly installments, in each case subject to each such Optionee's continued employment with the Company as of the applicable vesting dates. The stock options are subject to the terms and conditions of the Company's 2015 New Employee Incentive Plan and the stock option agreements pursuant to which the stock options have been granted.

The stock options were granted as an inducement material to the Optionees' entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

About Cytori Therapeutics, Inc.

Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy(TM) acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy(TM) may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori's proprietary technologies and products. Cytori Nanomedicine(TM) is developing encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit

Cytori Therapeutics, Inc.

Tiago Girao


<img src="" alt="" width="1" height="1"/>

(C) Copyright 2018 GlobeNewswire, Inc. All rights reserved. ********************************************************************** As of Monday, 02-05-2018 23:59, the latest Comtex SmarTrend® Alert, an automated pattern recognition system, indicated a

Please read the End User Agreement.
By accessing this page, you agree to the terms and conditions of the End User Agreement.

News provided by COMTEX.

Lt Crude 61.21
Nat Gas 2.582
Corn 366
Cotton #2 79.57
Gold 1331.4
Copper 3.1750
Euro 1.23410
USD Index 89.780
SP500 E-mini 2712.25
DJIA E-mini 24926